Ambroxol as a novel disease-modifying treatment for Parkinson’s disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial

https://t.co/j2JCXOimK4 "One of the leading genetic risk factors for Parkinson's disease is being a carrier in the gene for β-Glucocerebrosidase (GCase; gene name GBA1)."

https://t.co/YCmYWw3Tbo

@Andron_1977 @lgj170 @HuiloAnti А вот и не брет https://t.co/q9ZX44C7mm

https://t.co/CmlYpId64G

RT @lateafternoon_k: @Shelleyhacek @laurieallee @dianaberrent @CircleDaydreams Ambroxol is a cheap & readily available drug used as an expe…

Ambroxol as a novel disease-modifying treatment for Parkinson’s disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial #LongCovid https://t.co/24OeeuCj2o

@Shelleyhacek @laurieallee @dianaberrent @CircleDaydreams Ambroxol is a cheap & readily available drug used as an expectorant that has some action on the plaques that form in Alzheimer’s. I take it for long Covid & my brain fog is less bad on it. h

RT @LewyBodyWarrior: Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, random…

RT @LewyBodyWarrior: Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, random…

RT @LewyBodyWarrior: Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, random…

Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-c... - PubMed - NCBI https://t.co/nlgaLhfDrC

なお通常量の20倍以上とかアホみたいな量を使う模様

去痰で用いられるアンブロキソール（ムコソルバン）は、βグルコセレブロシダーゼを増やすことによってαシヌクレインを減少させ、認知症を伴うパーキンソン病に有効かもしれないとのこと。ほんまかいな。 https://t.co/evIfZKExU9 https://t.co/FFzCq27llR

@HarvardMIT_CRS @MassGeneralMDs @HiTSatHarvard Repurpose a old cough medicine #Ambroxol Feb 9, 2019 - Study by Western University Health Science, Ontario, Canada: Ambroxol as a novel disease-modifying treatment for Parkinson’s disease dementia https://t.

@KentSmalley Another trial to lower α-synuclein - with cough medicine. Feb 9, 2019 - Study by Western University Health Science, Ontario, Canada: Ambroxol as a novel disease-modifying treatment for Parkinson’s disease dementia https://t.co/6qRVVV9XY2

Feb 9, 2019 - Study by Western University Health Science, Ontario, Canada: Ambroxol as a novel disease-modifying treatment for Parkinson’s disease dementia https://t.co/6qRVVV9XY2

RT @ScienceofPD: The protocol of the Ambroxol as a novel disease-modifying treatment for #Parkinsons disease dementia clinical trial at @We…

Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial. https://t.co/iLJwySjJEd

The protocol of the Ambroxol as a novel disease-modifying treatment for #Parkinsons disease dementia clinical trial at @WesternU has been published. Hopefully the results will be available later this year. https://t.co/UcHobLGRPd https://t.co/U6F02CnY5w

Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-c... - PubMed - NCBI https://t.co/IbBWGrxEZn

So proud of working on this study testing the drug Ambroxol as a potential disease-modifying treatment for #Parkinsons disease #dementia. Recruitment still ongoing and protocol just published https://t.co/UHuDrU4Mfe @lawsonresearch @ParkwoodInstRes

Ambroxol as a novel disease-modifying treatment for Parkinson’s disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial https://t.co/QbkiBaIMDe #bmcneurol

Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial. https://t.co/rPS04tOIX0 https://t.co/m4dTKdhCh9